Gleamer acquired by Radnet
Context
RadNet acquired Gleamer in an all-cash transaction to integrate its automated diagnostic and reporting solutions into the DeepHealth platform. The acquisition aims to create the world's largest provider of clinical radiology AI solutions by combining RadNet's massive US imaging volume with Gleamer's advanced multi-modality software. Gleamer will now operate as RadNet’s French subsidiary, with founder Christian Allouche continuing to lead development from Paris. The strategic goal is to automate routine imaging workflows—specifically plain-film X-rays, which represent 25% of RadNet’s volume—to drive significant cost efficiencies and diagnostic accuracy.
It is worth noting that the fund Supernova Invest / Heal Capital took control of Gleamer through an LBO in 2023.
Gleamer, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x in 2026).
-> Deep-dive in Healthcare & Pharma market trends
Target
Gleamer is a leading French MedTech company specializing in artificial intelligence for medical imaging. Its "Copilot" platform provides automated diagnostic assistance for radiologists across multiple modalities, including X-ray, Mammography, and MRI. Prior to this acquisition, Gleamer consolidated the market by acquiring Pixyl and Caerus Medical in 2025, expanding its expertise into neuro and lumbar MRI. The company serves over 700 clients in 44 countries, with its solutions supporting over 25 clinical indications.
Ent. Value
€100–350M
Equity Value
[members only]
Multiples
EV / Revenue
4x–10x
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Gleamer
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2023 | SUPERNOVA INVEST / HEAL CAPITAL | GLEAMER | FRANCE | Health Tech |
Other operations with Radnet
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2022 | RADNET | HEART & LUNG IMAGING | UNITED KINGDOM | Radiology |
Similar deals in Healthcare Services
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 08/2026 | AGENTIS HEALTH GROUP | CLINICAL PHARMACIST SOLUTIONS | UNITED KINGDOM | Healthcare Services |
| 04/2026 | APOLLO GLOBAL MANAGEMENT | MEDICAL-SURGICAL SOLUTIONS | UNITED STATES | Hospital Logistics |
| 03/2026 | THERMO FISHER SCIENTIFIC | CLARIO HOLDINGS | UNITED STATES | CRO / Clinical Trials |
| 01/2026 | SAGARD | QUIPMENT | FRANCE | Healthcare Services |
| 01/2026 | ANTIN INFRASTRUCTURE | EMSERE | NETHERLANDS | CRO / Clinical Trials |
| 01/2026 | TPG | OPTUM UK | UNITED KINGDOM | Health Tech |
| 01/2026 | PERMIRA | CARNE GROUP | IRELAND | Healthcare Services |
| 12/2025 | PHARMA EQUITY GROUP | OTIOM | DENMARK | Health Tech |
| 11/2025 | ASKER HEALTHCARE GROUP | FINMED GROUP | FRANCE | Hospital Logistics |
| 11/2025 | EURAZEO | EXCELYA | FRANCE | CRO / Clinical Trials |
REFERENCES
Valuation range: EV €100–350M
Revenue range: €25–50M
EV/Revenue range: 4x - 10x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Gleamer by Radnet are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: gleamer
FAQ
What transaction does this page cover?
How was the acquisition of Gleamer by Radnet valued, and what multiples were paid?
What was Gleamer’s revenue at the time of the deal?
How does the valuation of Gleamer compare to benchmarks in the Healthcare & Pharma sector?
What sources support the information on this transaction?
What is mynth?